Enterprise Value

-12.72M

Cash

25.19M

Avg Qtr Burn

-5.741M

Short % of Float

0.90%

Insider Ownership

0.00%

Institutional Own.

6.46%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PHAXIAM phages Details
Endocarditis infections, Staph aureus

Phase 1

Data readout

Eryaspase (GRASPA) (asparaginase) Details
Pancreatic cancer, Solid tumor/s, Cancer

Failed

Discontinued

Eryaspase (GRASPA) (asparaginase) Details
Leukemia, Acute lymphoblastic leukemia, Cancer

Failed

Discontinued

Failed

Discontinued

Eryaspase (GRASPA) (asparaginase) Details
Breast cancer, Triple-negative breast cancer , Cancer

Failed

Discontinued